Walleye Trading
BCRX icon

Walleye Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,200
Closed -$314K – 4143
2025
Q4 		$314K Buy
+40,200
New +$291K ﹤0.01% 3125
2024
Q1 		– Sell
-5,100
Closed -$30.5K – 4762
2023
Q4 		$30.5K Sell
5,100
-10,700
-68% -$62K ﹤0.01% 4439
2023
Q3 		$112K Buy
15,800
+8,600
+119% +$61.8K ﹤0.01% 3913
2023
Q2 		$50.7K Sell
7,200
-3,600
-33% -$28.9K ﹤0.01% 3960
2023
Q1 		$90.1K Sell
10,800
-87,500
-89% -$842K ﹤0.01% 3894
2022
Q4 		$1.13M Buy
98,300
+59,600
+154% +$743K ﹤0.01% 2127
2022
Q3 		$488K Buy
38,700
+29,800
+335% +$383K ﹤0.01% 2931
2022
Q2 		$94K Sell
8,900
-10,300
-54% -$106K ﹤0.01% 4134
2022
Q1 		$312K Sell
19,200
-121,300
-86% -$1.95M ﹤0.01% 3412
2021
Q4 		$1.95M Sell
140,500
-100,500
-42% -$1.33M 0.01% 1669
2021
Q3 		$3.46M Buy
241,000
+19,200
+9% +$303K 0.01% 1151
2021
Q2 		$3.51M Buy
+221,800
New +$3.01M 0.01% 1030
2021
Q1 		– Sell
-3,600
Closed -$27K – 4806
2020
Q4 		$27K Buy
+3,600
New +$18.6K ﹤0.01% 4337

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Walleye Trading's BCRX Position: Q1 2026 in Review

Walleye Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 23,777 shares — an estimated $185K sold.

Walleye Trading first reported a position in BCRX in Q2 2015 and held it in 19 quarters. The position peaked at $1.79M in Q3 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Walleye Trading reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 23,777 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $185K.
  • Walleye Trading first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Walleye Trading's BioCryst Pharmaceuticals position peaked at $1.79M in Q3 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.